Re-stimulated tumor-infiltrating lymphocytes (TILs)

Phase 1Cell therapy

Re-stimulated tumor-infiltrating lymphocytes (TILs) is one of 3 biologic programs targeting Platinum-resistant. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Platinum-ResistantActive, not recruiting

Platinum-ResistantPhase 1

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Platinum-Resistant

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 1

1 2

Interleukin 2

EEssen Biotech

Phase 1

1 3

Re-stimulated tumor-infiltrating lymphocytes (TILs)

UUniversity Health Network, Toronto

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Platinum-Resistant

NCT01883297

Clinical

Trials by Indication[1]

Platinum-resistant1 trial

Phase I Study Evaluating the Feasibility and Safety of Infusion of "Re-Stimulated" Autologous TILs Followed by Low-Dose IL-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting·UUniversity Health Network, Toronto·Phase 1·NCT01883297·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Re-stimulated tumor-infiltrating lymphocytes (TILs). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Re-stimulated tumor-infiltrating lymphocytes (TILs) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Re-stimulated tumor-infiltrating lymphocytes (TILs). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Health Network, Toronto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: UUniversity Health Network, Toronto

Re-stimulated tumor-infiltrating lymphocytes (TILs)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Platinum-resistant1 trial

References

Drug Info

Quick Facts

Related News